T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan Inc
AGN
|
+$1.3B |
| 2 |
American Airlines Group
AAL
|
+$853M |
| 3 |
Intuitive Surgical
ISRG
|
+$816M |
| 4 |
Morgan Stanley
MS
|
+$681M |
| 5 |
Wynn Resorts
WYNN
|
+$622M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Procter & Gamble
PG
|
+$1.4B |
| 2 |
eBay
EBAY
|
+$763M |
| 3 |
DISCK
Discovery, Inc. Series C Common Stock
DISCK
|
+$760M |
| 4 |
Broadcom
AVGO
|
+$757M |
| 5 |
US Bancorp
USB
|
+$686M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.64% |
| 2 | Consumer Discretionary | 13.46% |
| 3 | Financials | 12.79% |
| 4 | Industrials | 12.13% |
| 5 | Technology | 9.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
826
Diodes
DIOD
$4.48B
| $56.1M | 0.01% |
1,938,322
-1,445,610
| -43% | -$40M |
|
827
Descartes Systems
DSGX
$6.62B
| $56M | 0.01% |
+3,905,249
| New | +$53M |
|
828
Chubb
CB
$133B
| $56M | 0.01% |
539,770
-1,000
| -0.2% | -$102K |
|
829
Travelers Companies
TRV
$77.2B
| $55.6M | 0.01% |
591,177
+10,580
| +2% | +$965K |
|
830
Vanda Pharmaceuticals
VNDA
$304M
| $55.4M | 0.01% |
3,426,791
+1,674,910
| +96% | +$22.3M |
|
|
STFC
831
DELISTED
State Auto Financial Corp
STFC
| $55.2M | 0.01% |
2,353,946
+4,600
| +0.2% | +$100K |
|
832
Truist Financial
TFC
$64.7B
| $55M | 0.01% |
1,395,467
+34,400
| +3% | +$1.32M |
|
833
Aflac
AFL
$60.7B
| $55M | 0.01% |
1,767,626
-47,600
| -3% | -$1.49M |
|
|
FARO
834
DELISTED
Faro Technologies
FARO
| $54.7M | 0.01% |
1,112,760
+4,410
| +0.4% | +$202K |
|
|
BEL
835
DELISTED
Belmond Ltd.
BEL
| $54.6M | 0.01% |
3,757,090
-10,700
| -0.3% | -$142K |
|
|
TWTC
836
DELISTED
TW TELECOM INC CL A COM
TWTC
| $54.6M | 0.01% |
1,353,890
-933,380
| -41% | -$30.8M |
|
837
Zumiez
ZUMZ
$319M
| $54.5M | 0.01% |
1,977,000
-1,061,760
| -35% | -$28.2M |
|
838
Moody's
MCO
$84.6B
| $54.1M | 0.01% |
617,406
-9,500
| -2% | -$783K |
|
|
CLVS
839
DELISTED
Clovis Oncology, Inc.
CLVS
| $54M | 0.01% |
1,303,051
+226,025
| +21% | +$11.6M |
|
840
Brown-Forman Class B
BF.B
$12.9B
| $53.9M | 0.01% |
1,789,200
-167,109
| -9% | -$4.89M |
|
841
Ultragenyx Pharmaceutical
RARE
$2.6B
| $53.7M | 0.01% |
1,253,279
-137,700
| -10% | -$5.67M |
|
|
SLCA
842
DELISTED
U.S. SILICA HOLDINGS, INC.
SLCA
| $53.7M | 0.01% |
968,070
-207,476
| -18% | -$9.77M |
|
|
GLOG
843
DELISTED
GASLOG LTD
GLOG
| $53.6M | 0.01% |
1,680,570
-54,874
| -3% | -$1.44M |
|
844
Silicon Laboratories
SLAB
$7.28B
| $53.3M | 0.01% |
1,082,010
-52,710
| -5% | -$2.51M |
|
|
PARA
845
DELISTED
Paramount Global Class B
PARA
| $53.2M | 0.01% |
856,189
-15,620
| -2% | -$930K |
|
|
HAYN
846
DELISTED
Haynes International, Inc.
HAYN
| $53.1M | 0.01% |
937,998
-700
| -0.1% | -$37.8K |
|
|
FCS
847
DELISTED
FAIRCHILD SEMICONDUCTOR INTL INC COMMON
FCS
| $53M | 0.01% |
3,399,630
-819,160
| -19% | -$11.6M |
|
|
ACC
848
DELISTED
American Campus Communities, Inc.
ACC
| $52.9M | 0.01% |
1,382,610
+54,503
| +4% | +$2.09M |
|
|
VIVO
849
DELISTED
Meridian Bioscience Inc
VIVO
| $52.8M | 0.01% |
2,557,305
-75,030
| -3% | -$1.54M |
|
850
Mativ Holdings
MATV
$667M
| $52.7M | 0.01% |
1,207,585
+1,195,725
| +10,082% | +$50.2M |
|
Similar funds
T. Rowe Price Associates's Q2 2014 Portfolio in Review
As of Q2 2014, T. Rowe Price Associates held 2,596 positions worth $463B, up 3.9% from $445B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
T. Rowe Price Associates's Q2 2014 filing shows 97 new, 1,091 increased, 793 reduced and 67 closed positions. Its largest new stake was Teva Pharmaceuticals: 4,638,481 shares worth $243M. The largest sale was Procter & Gamble, an estimated $1.4B.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q2 2014 buy was Teva Pharmaceuticals: 4,638,481 shares worth $243M.
- T. Rowe Price Associates added most to Allergan Inc in Q2 2014, an estimated $1.3B increase.
- T. Rowe Price Associates's biggest Q2 2014 reduction was Procter & Gamble, cutting an estimated $1.4B.
- T. Rowe Price Associates fully exited Santander in Q2 2014, selling an estimated $134M.
- T. Rowe Price Associates's ten largest holdings make up 12% of its $463B portfolio in Q2 2014.
- T. Rowe Price Associates opened 97 new positions and closed 67 in Q2 2014.
- T. Rowe Price Associates's portfolio value rose 3.9% quarter-over-quarter to $463B.
Based on T. Rowe Price Associates's 13F filing for Q2 2014, filed 14 Aug 2014.